
A one-time infusion of CRISPR gene editing therapy slashed dangerous cholesterol by 52%, with the patients still experiencing the benefit 12 months after initial treatment, and without side effects.
The Cleveland Clinic in Ohio reported that their Phase 1 human trial showed a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing “bad” LDL cholesterol and triglycerides by nearly half in patients throughout a one-year follow-up, after their disorder had previously been resistant to medication.
The trial, which included 15 patients, aimed to see if the reductions in LDL cholesterol and triglycerides previously reported after two months would persist for 12 months. After 12 months, patients who were treated with the highest dose saw a 52.5% lowering from baseline in LDL cholesterol, and a 47.8% reduction in triglycerides. There were no serious adverse events related to the therapy during the one-year follow-up.
The study, published in the New England Journal of Medicine in August, was funded by CRISPR Therapeutics AG in Switzerland.
“The durability of the lipid-lowering effect was impressive,” said Cleveland Clinic cardiologist Dr. Luke Laffin, the first author of the study.
“It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.”
CRISPR-Cas9 is a gene-editing technology that can be used to modify or correct specific regions of a person’s DNA to treat serious diseases.
This trial tested CTX310, an experimental CRISPR-Cas9 gene-editing treatment that is delivered as a one-time infusion. CTX310 carries the CRISPR editing mechanism into the liver, where it switches off a gene called ANGPTL3. Turning off this gene can lower LDL cholesterol and triglycerides, which are both linked to heart disease.
During the trial, CTX310 was administered at doses from 0.1 to 0.8 mg/kg during the single infusion, after pre-treatment with corticosteroids and antihistamines. Participants were monitored for safety of the treatment, and the effects of this gene therapy on ANGPTL3, LDL cholesterol and triglyceride levels. CTX310 reduced both LDL cholesterol and triglycerides by approximately 50% on average at the highest dose 12 months after the treatment.
The study participants were monitored for one year following the trial, with additional long-term safety follow-up planned for the next 15 years, as recommended by the FDA for all gene-editing therapies.
Additionally, the results of a related study were presented last week at the American Heart Association’s annual meeting in Chicago, showing the CTX310 therapy slashed dangerous triglyceride levels by 63%–85% in 10 adults with severe hyper-triglyceridemia—and it only took 30 days after receiving a single injection.
SHARE THE EXCITING NEWS With Family On Social Media…











